Cytosorbents Crp (CTSO) Peer Comparison

$0.34

$0.00 (-0.13%)

As on 28-Aug-2026 13:33EDT

Market cap

$23 Mln

Revenue (TTM)

$37 Mln

P/E Ratio

--

P/B Ratio

11.4

Div. Yield

0 %

Edit

	Cytosorbents Crp (CTSO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	23	12,753	10,906	10,222	9,762
Revenue ($ Mln)	37	1,505	613	785	2,589
Net Profit ($ Mln)	-18.21	160.59	-188.05	41.54	222.40
Net Margin (%)	-48.94	10.67	-30.68	5.29	8.59
RoE (%)	--	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.57	44.47
Price-To-Book	11.43	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Cytosorbents Crp (CTSO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	37.22	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	10.57	483.98	127.96	384.30	1,245.50
Gross Profit	26.49	942.44	393.22	347.62	1,343.60
Operating Expenses	39.07	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-12.42	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-18.61	203.83	-192.83	52.15	350.40
Provision for Tax	-0.40	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-18.21	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Cytosorbents Crp (CTSO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	-0.75	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	14.69	210.18	135.71	705.49	2,116.80
Current Liabilities	24.02	233.78	102.33	132.66	961.30
Total Liabilities	44.18	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Cytosorbents Crp (CTSO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	22.22	630.60	404.74	1,749.63	7,231.50
Current Assets	15.74	1,344.12	515.78	1,200.55	3,020.50
Total Assets	44.18	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	26.33	212.71	102.84	690.94	1,203.70
Net Current Assets	-8.29	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Cytosorbents Crp (CTSO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-12.38	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-0.42	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	9.31	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Cytosorbents Crp (CTSO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-22.46	11.76	-22.53	1.79	8.98
ROE (%)	-96.39	10.86	-28.10	1.97	3.04
ROA (%)	-30.40	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-41.64	13.63	-30.58	9.87	-5.99
Net Margin (%)	-48.94	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Cytosorbents Crp (CTSO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	3.07	17.55	41.55	16.49	1.37
EBIT Growth (%)	-72.07	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	-86.81	8.72	-102.66	400.42	-30.32
EPS Growth (%)	-59.14	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-106.93	17.33	-12.65	2.16	2.19

Valuation Ratios

	Cytosorbents Crp (CTSO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-4.90	68.93	-34.59	189.42	--
Price / Book Value	6.80	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-14.46	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Cytosorbents Crp (CTSO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	-4.12	0.00	0.00	0.26	0.11
Short term debt to equity ratio	-19.62	0.01	0.00	0.01	0.06
Current Ratio	0.66	5.75	5.04	9.05	3.14
Quick Ratio	0.50	3.86	4.46	7.64	2.33
Interest Coverage	-4.97	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Cytosorbents Crp (CTSO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	18.23	12.65	22.67	20.09	17.06
Asset Turnover	0.62	0.74	0.59	0.26	0.24
Receivable days	73.27	46.54	60.95	72.41	65.39
Inventory Days	138.44	331.92	193.84	146.53	221.09
Payable days	107.25	26.16	60.19	29.05	37.02
Cash Conversion Cycle	104.45	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly